Brentuximab Vedotin (SGN-35), an antibody–drug conjugate for the treatment of CD30-positive malignancies

ISSN： 1354-3784

Source： Expert Opinion on Investigational Drugs, Vol.21, Iss.2, 2012-02, pp. : 205-216

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

SGN-30: a basis for the effective treatment of CD30 positive hematopoietic malignancies

By Pinter-Brown Lauren C

Expert Opinion on Investigational Drugs, Vol. 17, Iss. 12, 2008-12 ,pp. : 1883-1887

Informa Healthcare

Access to resources Recommend Favorite

Antibody-Drug Conjugate Targets

Current Cancer Drug Targets, Vol. 9, Iss. 8, 2009-12 ,pp. : 982-1004

Bentham Science Publishers

Access to resources Recommend Favorite

Brentuximab Vedotin

Drugs in R&D, Vol. 11, Iss. 1, 2011-03 ,pp. : 85-95

Adis International

Access to resources Recommend Favorite

Investigational antibody-drug conjugates for hematological malignancies

By Polson Andrew G Ho William Y Ramakrishnan Vanitha

Expert Opinion on Investigational Drugs, Vol. 20, Iss. 1, 2011-01 ,pp. : 75-85

Informa Healthcare

Access to resources Recommend Favorite

Brentuximab vedotin: delivering an antimitotic drug to activated lymphoma cells

By Ansell Stephen M

Expert Opinion on Investigational Drugs, Vol. 20, Iss. 1, 2011-01 ,pp. : 99-105

Informa Healthcare

Access to resources Recommend Favorite